Table 3.

Chemotherapy regimens commonly used in recurrent glioblastoma

Temozolomide	Conventional	150 mg/m2 (200 mg/m2 if no previous CT) × 5 days every 28 days
	Extended schedules	50 mg/m2/day continuous
		75–100 mg/m2 d1–d21 every 28 days
		150 mg/m2 for 7 days every 14 days
BCNU	200 mg/m2 iv every 6–8 weeks
CCNU	100–130 mg/m2 po every 6 weeks
Fotemustine	Addeo schedule	80 mg/m2 day 1, 15, 30, 45, 60 followed by a rest lost 4 weeks and a maintenance phase of 80 mg/m2 every 4 weeks
	Brandes schedule	75 mg/m2 days 1, 8 and 15 followed by a rest lost 5 weeks and a maintenance phase of 100 mg/m2 every 3 weeks
	Fabrini schedule	100 mg/m2 days 1, 8 and 15 followed by a rest lost 4–6 weeks and a maintenance phase of 100 mg/m2 every 3 weeks
PCV	Every 6 weeks	Procarbazine 60 mg/m2 days 8–21 CCNU 110 mg/m2 d1 Vincristine 1.4 mg/m2 days 8 and 29
Bevacizumab (BEV)	Monotherapy	10 mg/kg every 14 days
	Plus irinotecan (IT)	BEV 10 mg/kg + IT 125 mg/m2 every 2 weeks
	Plus CCNU	10 mg/kg every + CCNU 90 mg/m2 14 days
	Plus fotemustine	75 mg/m2 days 1, 8 followed after 3 weeks arrest 75 m/m2 every 6 weeks
Carboplatinum	AUC 5 every 4 weeks